Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
ModafinilCat. No. 1811 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Alternative Name: CRL 40476 Chemical Name: 2-[(Diphenylmethyl)sulfinyl]acetamide |
Biological Activity
Psychostimulant that displays neuroprotective and antiparkinsonian activity in a primate model of Parkinson's disease. Promotes vigilence and wakefulness without the central and peripheral side effects associated with conventional dopaminergic psychostimulants. Mechanism of action is not fully understood, possibly via modulation of catecholamine/GABAergic neurotransmission.Certificate of Analysis / Safety Data Sheet
References
Ferraro et al (1997) Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol.Psychiatry 42 1181. PMID: 9426889.
Jenner et al (2000) Antiparkinsonian and neuroprotective effects of modafinil in the mtpt-treated common marmoset. Exp.Brain Res. 133 178. PMID: 10968218.
Madras et al (2006) Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J.Pharmacol.Exp.Ther. 319 561. PMID: 16885432.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Modafinil, supplier, Psychostimulant, Adrenergic, Compounds, Adrenoceptors, Receptors, Dopaminergic, Dopamine, GABA, CRL40476
Quick Order
Find multiple products by catalog number
Cardiovascular Guide
Request your free copy
Highlights over 250 products for cardiovascular research. Request a copy or view PDF today.
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
Regulation of Vascular Reactivity by GPCRs
Written by J.J. Maguire and A.P. Davenport
'Regulation of Vascular Reactivity by G-protein-coupled Receptors' summarizes the key GPCRs regulating vascular reactivity.
Antidepressants - Current and Future Targets
Written by P. Skolnich et al
'Antidepressants - Current and Future Targets' provides an overview of the current and future targets for the treatment of major depressive disorder.
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.